1. Home
  2. INDP vs NXPL Comparison

INDP vs NXPL Comparison

Compare INDP & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • NXPL
  • Stock Information
  • Founded
  • INDP 2000
  • NXPL 1997
  • Country
  • INDP United States
  • NXPL United States
  • Employees
  • INDP N/A
  • NXPL N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • NXPL Telecommunications Equipment
  • Sector
  • INDP Health Care
  • NXPL Telecommunications
  • Exchange
  • INDP Nasdaq
  • NXPL Nasdaq
  • Market Cap
  • INDP 15.4M
  • NXPL 21.9M
  • IPO Year
  • INDP N/A
  • NXPL N/A
  • Fundamental
  • Price
  • INDP $1.55
  • NXPL $1.18
  • Analyst Decision
  • INDP Strong Buy
  • NXPL
  • Analyst Count
  • INDP 1
  • NXPL 0
  • Target Price
  • INDP $12.00
  • NXPL N/A
  • AVG Volume (30 Days)
  • INDP 27.3K
  • NXPL 45.8K
  • Earning Date
  • INDP 11-04-2024
  • NXPL 11-12-2024
  • Dividend Yield
  • INDP N/A
  • NXPL N/A
  • EPS Growth
  • INDP N/A
  • NXPL N/A
  • EPS
  • INDP N/A
  • NXPL N/A
  • Revenue
  • INDP N/A
  • NXPL $66,404,000.00
  • Revenue This Year
  • INDP N/A
  • NXPL N/A
  • Revenue Next Year
  • INDP N/A
  • NXPL N/A
  • P/E Ratio
  • INDP N/A
  • NXPL N/A
  • Revenue Growth
  • INDP N/A
  • NXPL 498.52
  • 52 Week Low
  • INDP $1.03
  • NXPL $0.99
  • 52 Week High
  • INDP $3.25
  • NXPL $2.68
  • Technical
  • Relative Strength Index (RSI)
  • INDP 62.54
  • NXPL 42.90
  • Support Level
  • INDP $1.10
  • NXPL $1.35
  • Resistance Level
  • INDP $1.39
  • NXPL $1.37
  • Average True Range (ATR)
  • INDP 0.12
  • NXPL 0.11
  • MACD
  • INDP 0.05
  • NXPL -0.01
  • Stochastic Oscillator
  • INDP 100.00
  • NXPL 26.32

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About NXPL NextPlat Corp

NextPlat Corp is a global e-commerce and healthcare company. Its e-commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operate in two segments: e-Commerce Business and Healthcare Business.

Share on Social Networks: